Test Directory
| Test Code | |||
| CLCT | |||
| Test Name | |||
| Calcitonin | |||
| CPT Codes | |||
| 82308 | |||
| Expected Turnaround Time | |||
| 3 - 5 days | |||
| Clinical Utility | |||
|
Detection and confirmation C-cell hyperplasia (the precursor of medullary carcinoma of thyroid) as well as a tumor marker for diagnosis and management of medullary carcinoma of the thyroid gland. Preoperative serum calcitonin is reported to roughly correlate with tumor weight or extent of disease; therefore, postoperative levels also have prognostic application. The doubling time of serum levels correlates with a recurrence. Multiple endocrine neoplasia (MEN) type II includes medullary carcinoma of the thyroid, hyperparathyroidism, and pheochromocytoma (Sipple syndrome). MEN type IIB includes medullary carcinoma of the thyroid, pheochromocytoma, mucosal neuromas, marfanoid habitus, and intestinal ganglioneuromatosis. An important use of calcitonin assay is in follow-up of patients with medullary carcinoma and work-up of their families to detect early, subclinical cases. Indications for calcitonin assay include family history of unspecified type of thyroid cancer, calcified thyroid mass, thyroid tumor associated with hypercalcemia and/or pheochromocytoma, amyloid-containing metastatic carcinoma with unknown primary site and the presence of mucosal neuromas. |
|||
| Specimen and Container Info | |||
|
Specimen Type: Serum
Collection Container: Gold Top, Serum Separator Alternate Collection Container: Red Top, Plain Desired Specimen Volume: 1 mL |
|||
| Collection Instructions | |||
|
|||
| Processing and Submission Instructions | |||
|
|||
| Patient Preparation | |||
|
Patient should be fasting. |
|||
| Transport Instructions | |||
|
Transport to the laboratory frozen. |
|||
| Stability Requirements | |||
|
|||
| Causes for Rejection | |||
|
|||
| Methodology | |||
| Immunochemiluminometric Assay (Icma) | |||
| Reference Intervals | |||
|
See patient report. |
|||
| Limitations | |||
|
In a number of patients with medullary carcinoma of the thyroid (especially those with familial medullary carcinoma of thyroid) the baseline calcitonin may be normal; however, an abnormally large calcitonin response may follow provocative infusion of calcium and/or pentagastrin (usually 3 to 20 times baseline). Most subjects with microscopic medullary carcinoma and all with C-cell hyperplasia have normal basal calcitonin levels; provocative testing is needed (see the online Endocrine Appendix: Calcium-Pentagastrin Stimulation). Occasional spurious high results are encountered. Hemolysis can cause spurious high levels. Calcitonin in patients' sera lacks immunoreactive uniformity. Calcitonin is not a screening test. Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. |
|||
| Alternate Names | |||
|
|||
| Reference Lab | |||
| Labcorp Of America Holdings | |||
| Testing Schedule | |||
| Routine, 6 times per week | |||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.